Furthermore, the cross-talk between HER2 and ER pathways results in favorable clinical presentation and prognosis and reduced response to anti-HER2 treatment in HER2-positive breast cancer (Yarden and Sliwkowski, 2001; Baselga et al., 2017). The gene discussed is ERBB2; the disease is breast cancer.